S2302: PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Details
Age
Adult
Type of Study
Treatment
Locations
Rocky Mountain Regional VA Medical Center
Principal Investigator
Jessica Mcdermott, MD
Study ID
Protocol Number: 23-0174
More information available at ClinicalTrials.gov: NCT05633602
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers